May 26, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day 2020 on June 2 at 15.50 CET. The presentation will be livestreamed and can be followed at https://www.redeye.se/live/growth-day-2020.
Read morePress releases
All releases
InDex Pharmaceuticals presents at Redeye Growth Day 2020
26 May 2020
- Other press release
InDex Pharmaceuticals Holding AB (publ) interim report January – March 2020
07 May 2020
- Regulatory press release
FDA and EMA endorse the advancement of cobitolimod into phase III studies
Read moreBulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
20 April 2020
- Regulatory press release
April 20, 2020 – The annual general meeting in InDex Pharmaceuticals Holding AB (publ) was held on Monday 20 April 2020 at Setterwalls Advokatbyrå’s offices at Sturegatan 10 in Stockholm, Sweden. The following resolutions, amongst others, were passed at the general meeting:
Read moreInDex Pharmaceuticals advances cobitolimod further towards phase III following successful interactions with FDA and EMA
16 April 2020
- Regulatory press release
April 16, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has received positive responses from FDA and EMA regarding phase III development of the company's TLR9 agonist cobitolimod, for the treatment of moderate to severe ulcerative colitis. The company is continuing i...
Read moreUpdate on InDex Pharmaceuticals Holding AB’s (InDex) Annual General Meeting addressing covid-19
08 April 2020
- Other press release
April 8, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the company plans to hold its Annual General Meeting 2020 as scheduled at 5.00 pm on April 20, 2020, but takes precautionary measures. · Due to the risk for spread of infection InDex plans to limit the scope of the Annual Ge...
Read moreInDex Pharmaceuticals receives grant from Vinnova for pre-clinical development of DIMS compounds in inflammation
31 March 2020
- Other press release
31 mars 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that SEK 2.0 million has been granted from Sweden's innovation agency Vinnova to develop new, more effective and safer treatments for inflammatory diseases.
Read moreInDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2019
30 March 2020
- Regulatory press release
March 30, 2020 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2019. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/category/annual-reports/.
Read moreNotice to attend the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
19 March 2020
- Regulatory press release
N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the annual general meeting. In case of any discrepancies between the Swedish and English language versions, the Swedish version shall prevail. March 19, 2020 – The shareholders in InDex Pharmaceuticals H...
Read moreInDex Pharmaceuticals publishes mechanism of action data for cobitolimod in scientific journal
25 February 2020
- Other press release
February 25, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced the publication of scientific data on the mechanism of action of cobitolimod, the company’s lead drug candidate in development for the treatment of moderate to severe ulcerative colitis. The paper, published in the peer-reviewed Jou...
Read moreInDex Pharmaceuticals Holding AB (publ) year-end report 2019
20 February 2020
- Regulatory press release
Cobitolimod’s outstanding combination of efficacy and safety confirmed in in-depth analysis
Read moreInDex Pharmaceuticals’ in-depth analysis of the CONDUCT study confirms the successful top line results and supports the strategy going forward
19 February 2020
- Regulatory press release
February 19, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced the conclusions from in-depth analysis of the complete data set from the phase IIb dose optimisation study CONDUCT, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. T...
Read more